Intuitive Surgical (NASDAQ:ISRG) Given New $560.00 Price Target at Jefferies Financial Group

Key Points

• Jefferies Financial Group has raised its price target for Intuitive Surgical from $550.00 to $560.00, maintaining a "hold" rating, which suggests a potential upside of 5.71% from the current price.
• Intuitive Surgical reported quarterly earnings of $2.40 per share, exceeding analyst expectations, with revenues of $2.51 billion, marking a 22.9% increase year-over-year.
• The consensus price target for Intuitive Surgical among analysts is $604.50, with 18 analysts rating the stock as a buy, eight as a hold, and one as a sell.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) had its price objective hoisted by analysts at Jefferies Financial Group from $550.00 to $560.00 in a research note issued on Wednesday,MarketScreener reports. The firm presently has a "hold" rating on the medical equipment provider's stock. Jefferies Financial Group's price target would indicate a potential upside of 5.71% from the company's current price.

Other analysts have also issued reports about the stock. Wall Street Zen lowered shares of Intuitive Surgical from a "buy" rating to a "hold" rating in a research report on Saturday, October 18th. Robert W. Baird set a $655.00 target price on Intuitive Surgical in a report on Wednesday. Raymond James Financial set a $603.00 price target on Intuitive Surgical and gave the stock an "outperform" rating in a research report on Wednesday. Truist Financial set a $620.00 price objective on Intuitive Surgical and gave the company a "buy" rating in a research report on Wednesday. Finally, Piper Sandler boosted their target price on shares of Intuitive Surgical from $595.00 to $610.00 and gave the company an "overweight" rating in a research note on Wednesday. Eighteen investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Intuitive Surgical presently has an average rating of "Moderate Buy" and a consensus price target of $604.50.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $529.77 on Wednesday. The firm has a market capitalization of $189.91 billion, a price-to-earnings ratio of 70.12, a price-to-earnings-growth ratio of 4.86 and a beta of 1.61. Intuitive Surgical has a fifty-two week low of $425.00 and a fifty-two week high of $616.00. The stock's fifty day moving average is $455.28 and its two-hundred day moving average is $495.80.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, October 21st. The medical equipment provider reported $2.40 EPS for the quarter, topping the consensus estimate of $1.99 by $0.41. The business had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.41 billion. Intuitive Surgical had a net margin of 28.58% and a return on equity of 15.03%. The business's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.84 EPS. As a group, sell-side analysts forecast that Intuitive Surgical will post 6.43 EPS for the current fiscal year.

Insider Transactions at Intuitive Surgical

In other news, EVP Myriam Curet sold 4,500 shares of the stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the sale, the executive vice president owned 353 shares in the company, valued at approximately $173,845.44. This trade represents a 92.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Amy L. Ladd sold 336 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $470.11, for a total transaction of $157,956.96. Following the sale, the director owned 1,074 shares in the company, valued at $504,898.14. This represents a 23.83% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 45,224 shares of company stock worth $21,716,492 in the last three months. 0.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Intuitive Surgical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Chilton Capital Management LLC grew its stake in Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 43 shares in the last quarter. Tobam boosted its stake in Intuitive Surgical by 666.7% during the 2nd quarter. Tobam now owns 46 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 40 shares during the last quarter. Elite Financial Inc. acquired a new position in Intuitive Surgical during the 1st quarter worth $26,000. Kilter Group LLC acquired a new stake in shares of Intuitive Surgical in the 2nd quarter valued at about $27,000. Finally, LFA Lugano Financial Advisors SA bought a new position in shares of Intuitive Surgical during the first quarter worth about $30,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.